Incidence of hematologic malignancies is highest in adults with mixed chimerism following HCT for SCD
| . | NHLBI HLA matched . | NHLBI haploidentical . | Gene therapy . | French group . | CIBMTR . | |||
|---|---|---|---|---|---|---|---|---|
| Conditioning . | Alemtuzumab 300 cGy TBI . | Pentostatin/Cy alemtuzumab 300 cGy TBI . | (Chicago, Riyadh) alemtuzumab 300 cGy TBI . | Alemtuzumab 400 cGy TBI ± PTCy . | Pentostatin/Cy alemtuzumab 400 cGy TBI PTCy . | Busulfan . | Cy ± ATG busulfan . | Cy ± ATG busulfan (mostly) . |
| Number enrolled in the study | 57 | 24 | 64 | 21 | 19 | 44 | 234 | 908 |
| At-risk time (person-years) | 518.7 | 96 | Chicago: 123 Riyadh: 87.5 | 176.4 | 49.4 | 111.9 | 1848.6 | HLA-matched sibling: 1674 |
| Hematologic malignancies/ 100 person-years* | 0.57 | 2.08 | Chicago: 0.8 Riyadh: 0 | 1.70 | 0 | 1.79 | 0.05 | HLA-matched sibling: 0 |
| Median follow-up, y | 9.1 | 4.0 | 4 | 8.4 | 2.6 | 2.5 | 7.9 | 2.1-3.9 |
| . | NHLBI HLA matched . | NHLBI haploidentical . | Gene therapy . | French group . | CIBMTR . | |||
|---|---|---|---|---|---|---|---|---|
| Conditioning . | Alemtuzumab 300 cGy TBI . | Pentostatin/Cy alemtuzumab 300 cGy TBI . | (Chicago, Riyadh) alemtuzumab 300 cGy TBI . | Alemtuzumab 400 cGy TBI ± PTCy . | Pentostatin/Cy alemtuzumab 400 cGy TBI PTCy . | Busulfan . | Cy ± ATG busulfan . | Cy ± ATG busulfan (mostly) . |
| Number enrolled in the study | 57 | 24 | 64 | 21 | 19 | 44 | 234 | 908 |
| At-risk time (person-years) | 518.7 | 96 | Chicago: 123 Riyadh: 87.5 | 176.4 | 49.4 | 111.9 | 1848.6 | HLA-matched sibling: 1674 |
| Hematologic malignancies/ 100 person-years* | 0.57 | 2.08 | Chicago: 0.8 Riyadh: 0 | 1.70 | 0 | 1.79 | 0.05 | HLA-matched sibling: 0 |
| Median follow-up, y | 9.1 | 4.0 | 4 | 8.4 | 2.6 | 2.5 | 7.9 | 2.1-3.9 |
Bolded values represent: Incidence of hematologic malignancies/100 person-years.
Personal communication from C. Fitzhugh and courtesy of C. Fitzhugh CD (Blood. 2022;140(23):2514-2518).
CIBMTR, Center for International Blood and Marrow Transplant Research; Cy, cyclophosphamide; HLA, human leukocyte antigen; NHLBI, National Heart, Lung, and Blood Institute.